![]() ![]() Additional secondary endpoints are noted in table 1.Ĭonclusions: In our patient population, rates of hemostatic treatment failure were higher compared to the ANEXXA-4 study. ![]() 2 patients (10.5%) developed thrombotic complications (deep vein thrombosis, ST-elevation myocardial infarction, and ischemic stroke), and one patient developed ventricular tachycardia with chest pain (Patient not included due to not receiving the full infusion of AA). 15 patients had repeat neuroimaging within 24 hours after AA was administered with 7/15 (46.7%) noted to have progression of hematoma. Results: During the study period, 19 eligible patients receiving 20 doses (1 high-dose (800 mg bolus, followed by 8 mg/min) and 19 low-doses (400 mg bolus, followed by 4 mg/min)) of AA. Notable secondary endpoints included in-hospital mortality, incidence of thrombotic complications within 30 days, ICU and hospital length of stay (LOS), patient disposition, and change in National Institutes of Health Stroke Scale (NIHSS) and Modified Rankin Scale (mRS) at presentation and discharge. The primary endpoint of this study was the incidence of hemostatic treatment failure, indicated by progression of hematoma on neuroimaging within 24 hours of AA administration. Patients were excluded if they received multiple doses of AA during the same encounter, or both four-factor prothrombin complex concentrate (4F-PCC) and AA. Methods: This retrospective, single-center, observational study included adult patients with ICH who received AA for reversal of apixaban or rivaroxaban between Jand September 1, 2019. ![]() Theme: Coagulation and Natural Anticoagulants » Regulation of Coagulationīackground: In 2018, the FDA approval coagulation factor Xa for reversal of life-threatening or uncontrolled bleeding in patients receiving apixaban or rivaroxaban.Īims: To describe our experience with AA for reversal of apixaban and rivaroxaban in patients diagnosed with ICH. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |